Savara (NASDAQ:SVRA) Stock Price Down 5.1% – Should You Sell?

Savara Inc (NASDAQ:SVRA)’s share price dropped 5.1% during trading on Tuesday . The stock traded as low as $3.51 and last traded at $3.51. Approximately 390,156 shares traded hands during trading, a decline of 67% from the average daily volume of 1,193,072 shares. The stock had previously closed at $3.70.

Analysts Set New Price Targets

SVRA has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Savara in a research report on Tuesday, October 8th. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price objective on shares of Savara in a research report on Tuesday, October 1st. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $11.17.

Savara Stock Performance

The business has a fifty day simple moving average of $4.00 and a two-hundred day simple moving average of $4.24. The company has a debt-to-equity ratio of 0.26, a current ratio of 11.31 and a quick ratio of 11.31.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.01). On average, equities analysts predict that Savara Inc will post -0.44 earnings per share for the current year.

Institutional Investors Weigh In On Savara

A number of institutional investors and hedge funds have recently modified their holdings of SVRA. BNP Paribas Financial Markets lifted its stake in shares of Savara by 92.3% during the 1st quarter. BNP Paribas Financial Markets now owns 73,494 shares of the company’s stock worth $366,000 after acquiring an additional 35,269 shares during the last quarter. Jennison Associates LLC lifted its stake in shares of Savara by 0.3% during the 1st quarter. Jennison Associates LLC now owns 8,841,971 shares of the company’s stock worth $44,033,000 after acquiring an additional 26,613 shares during the last quarter. Swiss National Bank bought a new stake in shares of Savara during the 1st quarter worth approximately $732,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Savara during the 1st quarter worth approximately $394,000. Finally, ProShare Advisors LLC lifted its stake in shares of Savara by 9.0% during the 1st quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock worth $128,000 after acquiring an additional 2,114 shares during the last quarter. 87.93% of the stock is owned by institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.